PURPOSE: IFN-alpha is administered to melanoma patients and its endogenous production is essential for immune-mediated tumor recognition. We hypothesized that a reduced capacity for signal transducer and activator of transcription (STAT) 1 activation allows melanoma cells to evade the direct actions of IFN-alpha. EXPERIMENTAL DESIGN: Tyr(701)-phosphorylated STAT1 (P-STAT1) was measured by flow cytometry in IFN-alpha-stimulated human melanoma cell lines, melanoma cells derived from patient tumors, and peripheral blood mononuclear cells (PBMC). Expression of other Janus-activated kinase (Jak)-STAT intermediates (STAT1, STAT2, Jak1, tyrosine kinase 2, IFN-alpha receptor, STAT3, and STAT5) was evaluated by flow cytometry, immunoblot, or immunohistochemistry. RESULTS: Significant variability in P-STAT1 was observed in human melanoma cell lines following IFN-alpha treatment (P < 0.05) and IFN-alpha-induced P-STAT1 correlated with the antiproliferative effects of IFN-alpha (P = 0.042). Reduced formation of P-STAT1 was not explained by loss of Jak-STAT proteins or enhanced STAT5 signaling as reported previously. Basal levels of P-STAT3 were inversely correlated with IFN-alpha-induced P-STAT1 in cell lines (P = 0.013). IFN-alpha-induced formation of P-STAT1 was also variable in melanoma cells derived from patient tumors; however, no relationship between P-STAT3 and IFN-alpha-induced P-STAT1 was evident. Because IFN-alpha acts on both tumor and immune cells, we examined the ability of IFN-alpha to induce P-STAT1 in patient-derived melanoma cells and PBMCs. IFN-alpha induced significantly lower levels of P-STAT1 in melanoma cells compared with matched PBMCs (P = 0.046). Melanoma cells and human melanocytes required 10-fold higher IFN-alpha doses to exert P-STAT1 levels comparable with PBMCs. CONCLUSIONS: Melanoma cells are variable in their IFN-alpha responsiveness, and cells of the melanocytic lineage exhibit a lower capacity for IFN-alpha-induced Jak-STAT signaling compared with immune cells.
PURPOSE:IFN-alpha is administered to melanomapatients and its endogenous production is essential for immune-mediated tumor recognition. We hypothesized that a reduced capacity for signal transducer and activator of transcription (STAT) 1 activation allows melanoma cells to evade the direct actions of IFN-alpha. EXPERIMENTAL DESIGN:Tyr(701)-phosphorylated STAT1 (P-STAT1) was measured by flow cytometry in IFN-alpha-stimulated humanmelanoma cell lines, melanoma cells derived from patienttumors, and peripheral blood mononuclear cells (PBMC). Expression of other Janus-activated kinase (Jak)-STAT intermediates (STAT1, STAT2, Jak1, tyrosine kinase 2, IFN-alpha receptor, STAT3, and STAT5) was evaluated by flow cytometry, immunoblot, or immunohistochemistry. RESULTS: Significant variability in P-STAT1 was observed in humanmelanoma cell lines following IFN-alpha treatment (P < 0.05) and IFN-alpha-induced P-STAT1 correlated with the antiproliferative effects of IFN-alpha (P = 0.042). Reduced formation of P-STAT1 was not explained by loss of Jak-STAT proteins or enhanced STAT5 signaling as reported previously. Basal levels of P-STAT3 were inversely correlated with IFN-alpha-induced P-STAT1 in cell lines (P = 0.013). IFN-alpha-induced formation of P-STAT1 was also variable in melanoma cells derived from patienttumors; however, no relationship between P-STAT3 and IFN-alpha-induced P-STAT1 was evident. Because IFN-alpha acts on both tumor and immune cells, we examined the ability of IFN-alpha to induce P-STAT1 in patient-derived melanoma cells and PBMCs. IFN-alpha induced significantly lower levels of P-STAT1 in melanoma cells compared with matched PBMCs (P = 0.046). Melanoma cells and human melanocytes required 10-fold higher IFN-alpha doses to exert P-STAT1 levels comparable with PBMCs. CONCLUSIONS:Melanoma cells are variable in their IFN-alpha responsiveness, and cells of the melanocytic lineage exhibit a lower capacity for IFN-alpha-induced Jak-STAT signaling compared with immune cells.
Authors: Hla Win-Piazza; Valentina E Schneeberger; Liwei Chen; Daniele Pernazza; Harshani R Lawrence; Said M Sebti; Nicholas J Lawrence; Jie Wu Journal: Cancer Lett Date: 2012-02-01 Impact factor: 8.679
Authors: Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei Journal: Results Immunol Date: 2012-09-27
Authors: Megan C Duggan; Andrew R Stiff; Maryam Bainazar; Kelly Regan; Gonzalo N Olaverria Salavaggione; Sophia Maharry; James S Blachly; Madison Krischak; Christopher J Walker; Nicholas Latchana; Susheela Tridandapani; Albert de la Chapelle; Ann-Kathrin Eisfeld; William E Carson Journal: Proc Natl Acad Sci U S A Date: 2017-08-21 Impact factor: 11.205
Authors: Bethany L Mundy-Bosse; Gregory S Young; Todd Bauer; Elaine Binkley; Mark Bloomston; Matthew A Bill; Tanios Bekaii-Saab; William E Carson; Gregory B Lesinski Journal: Cancer Immunol Immunother Date: 2011-05-21 Impact factor: 6.968
Authors: Bethany L Mundy-Bosse; Gregory B Lesinski; Alena C Jaime-Ramirez; Kristen Benninger; Mahmood Khan; Periannan Kuppusamy; Kristan Guenterberg; Sri Vidya Kondadasula; Abhik Ray Chaudhury; Krista M La Perle; Melanie Kreiner; Gregory Young; Denis C Guttridge; William E Carson Journal: Cancer Res Date: 2011-06-16 Impact factor: 12.701
Authors: Gregory B Lesinski; Jason M Zimmerer; Melanie Kreiner; John Trefry; Matthew A Bill; Gregory S Young; Brian Becknell; William E Carson Journal: BMC Cancer Date: 2010-04-14 Impact factor: 4.430
Authors: Matthew A Bill; James R Fuchs; Chenglong Li; Jennifer Yui; Courtney Bakan; Don M Benson; Eric B Schwartz; Dalia Abdelhamid; Jiayuh Lin; Dale G Hoyt; Stacey L Fossey; Gregory S Young; William E Carson; Pui-Kai Li; Gregory B Lesinski Journal: Mol Cancer Date: 2010-06-25 Impact factor: 27.401
Authors: Gregory B Lesinski; Kristen Benninger; Melanie Kreiner; Megan Quimper; Gregory Young; William E Carson Journal: Cancer Immunol Immunother Date: 2009-04-26 Impact factor: 6.968